News See the latest press releases about Pentixapharm. Sebastian Bloszyk 1/6/26 Sebastian Bloszyk 1/6/26 Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension Read More Sebastian Bloszyk 12/3/25 Sebastian Bloszyk 12/3/25 Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension Read More Sebastian Bloszyk 11/11/25 Sebastian Bloszyk 11/11/25 Pentixapharm Publishes 9-Month Figures for 2025 Read More Sebastian Bloszyk 11/10/25 Sebastian Bloszyk 11/10/25 Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025 Read More Sebastian Bloszyk 11/6/25 Sebastian Bloszyk 11/6/25 Ad-hoc: Pentixapharm senkt Verlustprognose für das Geschäftsjahr 2025 deutlich Read More Sebastian Bloszyk 10/23/25 Sebastian Bloszyk 10/23/25 Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure Read More Sebastian Bloszyk 10/23/25 Sebastian Bloszyk 10/23/25 Ad-hoc: Pentixapharm fokussiert Entwicklung auf fortgeschrittene klinische Programme und stärkt finanzielle Position durch Einstellung präklinischer Aktivitäten Read More Sebastian Bloszyk 10/6/25 Sebastian Bloszyk 10/6/25 Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025 Read More Sebastian Bloszyk 9/25/25 Sebastian Bloszyk 9/25/25 Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial Read More Sebastian Bloszyk 8/5/25 Sebastian Bloszyk 8/5/25 Pentixapharm Publishes Half-Year Figures for 2025 Read More Sebastian Bloszyk 6/19/25 Sebastian Bloszyk 6/19/25 Pentixapharm Announces Encouraging Preclinical Data for First-in-Class Glycan-Dependent Anti-CD24 mAb Radiopharmaceutical GT-008 Read More Ad-hoc announcement Sebastian Bloszyk 5/27/25 Ad-hoc announcement Sebastian Bloszyk 5/27/25 Pentixapharm outlines new clinical development strategy Read More Phillip Eckert 4/25/25 Phillip Eckert 4/25/25 Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 Read More Phillip Eckert 4/24/25 Phillip Eckert 4/24/25 Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Read More Phillip Eckert 4/15/25 Phillip Eckert 4/15/25 Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year Read More Phillip Eckert 3/3/25 Phillip Eckert 3/3/25 Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG Read More Phillip Eckert 2/13/25 Phillip Eckert 2/13/25 First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 Read More Ad-hoc announcement Phillip Eckert 1/24/25 Ad-hoc announcement Phillip Eckert 1/24/25 Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million Read More Phillip Eckert 1/7/25 Phillip Eckert 1/7/25 Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope Read More Phillip Eckert 11/21/24 Phillip Eckert 11/21/24 First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach Read More Newer Posts Older Posts
Sebastian Bloszyk 1/6/26 Sebastian Bloszyk 1/6/26 Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension Read More
Sebastian Bloszyk 12/3/25 Sebastian Bloszyk 12/3/25 Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension Read More
Sebastian Bloszyk 11/11/25 Sebastian Bloszyk 11/11/25 Pentixapharm Publishes 9-Month Figures for 2025 Read More
Sebastian Bloszyk 11/10/25 Sebastian Bloszyk 11/10/25 Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025 Read More
Sebastian Bloszyk 11/6/25 Sebastian Bloszyk 11/6/25 Ad-hoc: Pentixapharm senkt Verlustprognose für das Geschäftsjahr 2025 deutlich Read More
Sebastian Bloszyk 10/23/25 Sebastian Bloszyk 10/23/25 Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure Read More
Sebastian Bloszyk 10/23/25 Sebastian Bloszyk 10/23/25 Ad-hoc: Pentixapharm fokussiert Entwicklung auf fortgeschrittene klinische Programme und stärkt finanzielle Position durch Einstellung präklinischer Aktivitäten Read More
Sebastian Bloszyk 10/6/25 Sebastian Bloszyk 10/6/25 Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025 Read More
Sebastian Bloszyk 9/25/25 Sebastian Bloszyk 9/25/25 Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial Read More
Sebastian Bloszyk 8/5/25 Sebastian Bloszyk 8/5/25 Pentixapharm Publishes Half-Year Figures for 2025 Read More
Sebastian Bloszyk 6/19/25 Sebastian Bloszyk 6/19/25 Pentixapharm Announces Encouraging Preclinical Data for First-in-Class Glycan-Dependent Anti-CD24 mAb Radiopharmaceutical GT-008 Read More
Ad-hoc announcement Sebastian Bloszyk 5/27/25 Ad-hoc announcement Sebastian Bloszyk 5/27/25 Pentixapharm outlines new clinical development strategy Read More
Phillip Eckert 4/25/25 Phillip Eckert 4/25/25 Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 Read More
Phillip Eckert 4/24/25 Phillip Eckert 4/24/25 Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Read More
Phillip Eckert 4/15/25 Phillip Eckert 4/15/25 Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year Read More
Phillip Eckert 3/3/25 Phillip Eckert 3/3/25 Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG Read More
Phillip Eckert 2/13/25 Phillip Eckert 2/13/25 First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 Read More
Ad-hoc announcement Phillip Eckert 1/24/25 Ad-hoc announcement Phillip Eckert 1/24/25 Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million Read More
Phillip Eckert 1/7/25 Phillip Eckert 1/7/25 Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope Read More
Phillip Eckert 11/21/24 Phillip Eckert 11/21/24 First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach Read More
